[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364141-105":59,"doc-detail-364141-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-trametinib-in-braf-v600mutant-advanced-melanoma","COMBI-I - Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma","","The COMBI-I trial (NCT02967692) evaluated spartalizumab plus dabrafenib and trametinib versus placebo plus dabrafenib and trametinib in BRAF V600–mutant unresectable or metastatic melanoma. The study did not achieve its primary progression-free survival endpoint at 24 months, and this final report describes overall survival from extended follow-up of at least 5 years. At the August 21, 2024 data cutoff (median follow-up 76.9 months), median OS was 61.5 months for the sparta-DabTram arm versus 41.6 months for placebo-DabTram (hazard ratio 0.760). Safety results matched known profiles, with pyrexia as the most common TRAE.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-trametinib-in-braf-v600mutant-advanced-melanoma/364141/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-trametinib-in-braf-v600mutant-advanced-melanoma/364141.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary endpoint for the COMBI-I trial, and what was reported here?","Question",{"text":112,"@type":113},"The COMBI-I trial did not reach its primary endpoint of progression-free survival at 24 months. This report presents final overall survival results from extended follow-up.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How long was the follow-up and what were the overall survival outcomes?",{"text":117,"@type":113},"At the August 21, 2024 cutoff, median follow-up was 76.9 months. Median OS was 61.5 months with sparta-DabTram versus 41.6 months with placebo-DabTram, with a hazard ratio of 0.760.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key safety findings reported in this analysis?",{"text":121,"@type":113},"Safety findings were consistent with the known sparta-DabTram profile. Pyrexia was the most common treatment-related adverse event, and grade ≥3 TRAEs occurred in 57.3% versus 36.7% of patients in the two arms.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364141,1790322436,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Clinical Trial Updates  \nCOMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma  \nAntoni Ribas, MD1  ; Caroline Robert, MD2,3  ; Dirk Schadendorf, MD4  ; Georgina V. Long, MD5  ; Hussein Tawbi, MD, PhD6  ; Keith Flaherty, MD7  ; Paolo A. Ascierto, MD8,9  ; Paul Nathan, MD10  ; Piotr Rutkowski, MD11  ; Oleg V. Leonov, MD12  ;  \nPaul Lorigan, MBBCh13 ; Sorilla Prey, MD, PhD14  ; Maristella Saponara, MD15  ; Ana Arance, MD16; Caroline Gaudy-Marqueste, MD, PhD17; Daniil Stroyakovskiy, MD18  ; Celeste Lebbe, MD, PhD19  ; Michele Maio, MD, PhD20  ; Michele Del Vecchio, MD21;  \nPamela Salman Boghikian, MD22  ; Ralf Gutzmer, MD23  ; Roberta Depenni, MD24; Marina Miskic, MD25; Mark Russo, MD, PhD26  ; and Reinhard Dummer, MD27   \nDOI [https://doi.org/10.1200/JCO-26-00528](https://doi.org/10.1200/JCO-26-00528)  \nABSTRACT  \nThe COMBI-I trial (ClinicalTrials.gov identiﬁer: NCT02967692) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n 5 267) versus placebo plus dabrafenib and trametinib (placebo-DabTram, n 5 265) for BRAF V600–mutant unresectable or metastatic melanoma failed to reach its primary end point of progression-free survival at 24 months. This ﬁnal analysis reports overall survival (OS) during at least 5 years of extended follow-up. At the end of the trial (August 21, 2024), the median duration of follow-up was 76.9 months (range, 73.7-83.3 months) . The median OS was 61.5 months (95% CI, 41.6 to not evaluable) for the sparta-DabTram arm and 41.6 months (95% CI, 30.6 to 56.9) for the placebo-DabTram arm (hazard ratio, 0.760 [95% CI, 0.598 to 0.966]) . The safety ﬁndings were consistent with the known safety proﬁle for sparta-DabTram. The most common treatment-related adverse event (TRAE) was pyrexia (65.9% v 46.2%, respectively, in the two study arms). Grade ≥3 TRAEs were reported in 57.3% and 36.7% of patients in the two arms, respectively. The combination of sparta-DabTram appears to improve OS compared with dabrafenib and trametinib alone inpatients with BRAF V600–mutant metastatic melanoma.  \nACCOMPANYING CONTENT  \n Appendix  \n Data Sharing Statement  \n Protocol  \nAccepted June 17, 2026 Published August 12, 2026  \nJ Clin Oncol 44:2490-2495 © 2026 by American Society of Clinical Oncology  \nView Online Article  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nBRAF and MEK inhibitors improve progression-free survival (PFS) and overall survival (OS) over other therapies and are currently approved for the treatment of patients with BRAFV600–mutant advanced melanoma.1 Patients with advanced melanoma, irrespective of driver aberrations in oncogenes, can be treated with immune checkpoint inhibitors.2 Previous studies have assessed the possibilities and outcomes of combining BRAF and MEK-targeted therapies with anti– PD-1/PD-L1 antibodies.3-13 The combination of atezolizumab with cobimetiniband vemurafenibis now approved by the US Food and Drug Administration as ﬁrst-line treatment for unresectable advanced BRAF V600–mutant melanoma.8 ,14  \nThe COMBI-I trial that evaluated the anti–PD-1 antibody spartalizumab in combination with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib (sparta-DabTram) over placebo plus dabrafenib and trametinib (placebo-  \nDabTram) did not meet its primary end point of improved median PFS (16 .2 months v 12 months; hazard ratio [HR], 0.82 [95% CI, 0.66 to 1.03]; P 5 .042, one-sided, nonsigniﬁcant) inpatients with unresectable or metastatic BRAF V600–mutant melanoma.15 Herein, we report the ﬁnal results for OS from the COMBI-I trial.  \nMETHODS  \nThe design of the phase III, randomized, double-blind, placebo-controlled COMBI-I trial (ClinicalTrials.gov identiﬁer: NCT02967692) has been published previously.15 Adult patients (age ≥18 years) with histologically conﬁrmed unresectable or metastatic BRAFV600–mutant cutaneous melanoma received intravenous spartalizumab (4","cbCailIy7QVVWaTD","https://ap.wps.com/l/cbCailIy7QVVWaTD","pdf",1007428,18,"English","# Abstract\n# Introduction\n# Methods\n# Results\n## Overall Survival","[{\"question\":\"What was the primary endpoint for the COMBI-I trial, and what was reported here?\",\"answer\":\"The COMBI-I trial did not reach its primary endpoint of progression-free survival at 24 months. This report presents final overall survival results from extended follow-up.\"},{\"question\":\"How long was the follow-up and what were the overall survival outcomes?\",\"answer\":\"At the August 21, 2024 cutoff, median follow-up was 76.9 months. Median OS was 61.5 months with sparta-DabTram versus 41.6 months with placebo-DabTram, with a hazard ratio of 0.760.\"},{\"question\":\"What were the key safety findings reported in this analysis?\",\"answer\":\"Safety findings were consistent with the known sparta-DabTram profile. Pyrexia was the most common treatment-related adverse event, and grade ≥3 TRAEs occurred in 57.3% versus 36.7% of patients in the two arms.\"}]","COMBI-I - Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma | PDF",1790155935,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5447a687843ad0b77b5b512f7cca4b99.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2fa7a2188ed70e56626817ca4fe6bb00.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92f6c5b8d0b8a5628e9f444f876ccd39.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e05144c947269761d26ed34592a5843.webp",980,1311]